Cantor Fitzgerald set a $150.00 price target on Neurocrine Biosciences (NASDAQ:NBIX) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the stock.
A number of other research analysts also recently weighed in on NBIX. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences to $127.00 and gave the company an overweight rating in a report on Monday, July 16th. Robert W. Baird restated an outperform rating and set a $122.00 price target (up previously from $100.00) on shares of Neurocrine Biosciences in a report on Wednesday, July 25th. BidaskClub upgraded shares of Neurocrine Biosciences from a hold rating to a buy rating in a report on Friday, July 27th. Jefferies Financial Group raised their price target on shares of Neurocrine Biosciences to $124.00 and gave the company a buy rating in a report on Monday, July 30th. Finally, Barclays raised their price target on shares of Neurocrine Biosciences from $100.00 to $135.00 and gave the company an overweight rating in a report on Wednesday, August 1st. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Neurocrine Biosciences presently has a consensus rating of Buy and a consensus target price of $125.50.
Shares of Neurocrine Biosciences stock traded down $3.67 during midday trading on Monday, reaching $106.88. 639,421 shares of the company’s stock traded hands, compared to its average volume of 744,943. The company has a market capitalization of $10.48 billion, a P/E ratio of -65.98, a P/E/G ratio of 37.22 and a beta of 0.94. The company has a current ratio of 9.19, a quick ratio of 9.19 and a debt-to-equity ratio of 1.00. Neurocrine Biosciences has a 52 week low of $67.32 and a 52 week high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.04. The business had revenue of $151.80 million for the quarter, compared to the consensus estimate of $151.51 million. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. Neurocrine Biosciences’s revenue for the quarter was up 149.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.13) EPS. On average, equities research analysts predict that Neurocrine Biosciences will post 0.15 earnings per share for the current year.
In related news, Director Richard F. Pops sold 5,500 shares of the firm’s stock in a transaction on Monday, October 29th. The shares were sold at an average price of $107.13, for a total value of $589,215.00. Following the transaction, the director now directly owns 37,759 shares in the company, valued at approximately $4,045,121.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary A. Lyons sold 15,000 shares of the firm’s stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $114.41, for a total transaction of $1,716,150.00. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.
A number of large investors have recently bought and sold shares of NBIX. Principal Financial Group Inc. grew its position in Neurocrine Biosciences by 1.6% in the 1st quarter. Principal Financial Group Inc. now owns 78,956 shares of the company’s stock worth $6,547,000 after purchasing an additional 1,234 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter worth $216,000. Fox Run Management L.L.C. acquired a new stake in Neurocrine Biosciences in the 3rd quarter worth $234,000. Swiss National Bank grew its position in Neurocrine Biosciences by 1.8% in the 2nd quarter. Swiss National Bank now owns 156,500 shares of the company’s stock worth $15,375,000 after purchasing an additional 2,800 shares during the last quarter. Finally, NumerixS Investment Technologies Inc grew its position in Neurocrine Biosciences by 90.9% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,100 shares of the company’s stock worth $204,000 after purchasing an additional 1,000 shares during the last quarter.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Read More: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.